EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study

Xinrong Zhang, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen

Digestive Diseases · 2024

DOI: 10.1159/000541945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases, 2024. Verfasst von Xinrong Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, School of Medicine, Stanford University Medical Center, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We compared clinical characteristics and outcomes in real-world metabolic dysfunction-associated steatotic liver disease (MASLD) patients with or without liver biopsy using a nationwide cohort in United States (USA) to fill in gaps in selection of biopsy patients.

Methods

We conducted a retrospective cohort study of adult MASLD patients using Marketscan® Databases (1/2007–12/2021). Patients were categorized into those with or without liver biopsy during follow-up.

Results

We analyzed 540,326 MASLD patients: 23,732 with and 516,594 without biopsy. Only 4% of MASLD patients received liver biopsy and biopsy rate decreased in the last 5 years (9.4%–3.6%). After 1:5 propensity score matching on baseline characteristics including age, sex, and comorbidities, a total of 23,731 patients with biopsy and 118,396 matched patients without biopsy were analyzed. The incidence per 1,000 person-years for hepatocellular carcinoma (HCC) was 0.22 versus 2.18, cirrhosis 29.75 versus 90.44, and hepatic decompensation 15.84 versus 28.25 compared patients with and without biopsy. In multivariable analysis, patients with biopsy had more than 9 times higher risk of developing HCC, 3 times higher risk of cirrhosis, and 78% higher risk of hepatic decompensation. In subgroup analysis, the association remained consistent when stratified by age (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHumansMaleFemaleMiddle AgedDisease ProgressionUnited StatesRetrospective StudiesBiopsyAdultLiver NeoplasmsLiverAgedCarcinoma, HepatocellularLiver CirrhosisIncidenceRisk Factors

Stichwörter der Autor:innen

CirrhosisHepatocellular carcinomaLiver biopsyLiver decompensationMetabolic dysfunction-associated steatohepatitis

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, School of Medicine, Stanford University Medical Center, Palo Alto, California, USA.
  • Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
  • Department of Epidemiology and Population Health, Stanford University, Palo Alto, California, USA.

Zitieren

APA

Zhang, X., Kam, L. Y., Barnett, S. D., Henry, L., Cheung, R., & Nguyen, M. H. (2024). Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study. Digestive Diseases. https://doi.org/10.1159/000541945

Vancouver

Zhang X, Kam LY, Barnett SD, Henry L, Cheung R, Nguyen MH. Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study. Digestive Diseases. 2024. doi:10.1159/000541945

BibTeX
@article{Zhang2024,
  author = {Zhang, Xinrong and Kam, Leslie Yeeman and Barnett, Scott D and Henry, Linda and Cheung, Ramsey and Nguyen, Mindie H},
  title = {Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study},
  journal = {Digestive Diseases},
  year = {2024},
  doi = {10.1159/000541945}
}
Kostenlos starten →